Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel vascularization strategies.

M Simons1

  • 1Angiogenesis Research Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. msimons@caregroup.harvard.edu

Idrugs : the Investigational Drugs Journal
|September 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative LVSI assessment in early-stage cervical cancer: Can it reliably guide lymph node management?

Gynecologic oncology·2026
Same author

Thermal asymmetry in the Moon's mantle inferred from monthly tidal response.

Nature·2025
Same author

Author Correction: Syndecan-2 selectively regulates VEGF-induced vascular permeability.

Nature cardiovascular research·2024
Same author

Stability of a Novel PEGylation Site on a Putative Haemoglobin-Based Oxygen Carrier.

Advances in experimental medicine and biology·2022
Same author

Syndecan-2 selectively regulates VEGF-induced vascular permeability.

Nature cardiovascular research·2022
Same author

Reporting guideline for interventional trials of primary and incisional ventral hernia repair.

The British journal of surgery·2021
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

New revascularization strategies, including angiogenesis and laser therapy, offer hope for advanced ischemic coronary disease patients ineligible for traditional treatments. Early trials and preclinical studies are exploring these novel approaches for improved outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Interventional Cardiology

Background:

  • A significant percentage of patients with advanced ischemic coronary disease lack options for conventional revascularization.
  • Standard treatments like angioplasty and bypass surgery are unsuitable for 20-30% of symptomatic patients due to disease complexity.

Purpose of the Study:

  • To review novel revascularization strategies for 'no-option' patients with advanced ischemic coronary disease.
  • To highlight emerging therapeutic approaches, specifically angiogenesis and laser revascularization.

Main Methods:

  • Presentation of early clinical trials involving angiogenic agents like vascular endothelial growth factor (VEGF165) and fibroblast growth factor 2 (FGF2).
  • Discussion of preclinical studies investigating delivery methods for angiogenic agents.

Related Experiment Videos

  • Validation of novel outcome measures for future clinical trials.

    • Main Results:

    • Early trials of angiogenic agents (VEGF165, FGF2) were presented.
    • Preclinical research explored effective delivery systems for therapeutic agents.
    • New outcome measures were identified for assessing treatment efficacy.

    Conclusions:

    • Angiogenesis and laser revascularization represent promising frontiers for patients with limited treatment choices.
    • Ongoing research is focused on optimizing delivery and outcome assessment for these innovative therapies.